Search research articles
Contact Us
Filters
Showing results (251-260 of 304) with videos related to
Page
of 31
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 18, 2021
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology
C Allison Stewart, Carl M Gay, Kavya Ramkumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2024
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities
C Allison Stewart, Lixia Diao, Yuanxin Xi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 3, 2016
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer
Vassiliki Papadimitrakopoulou, J Jack Lee, Ignacio I Wistuba, et al.
NPJ Precision Oncology
|
November 18, 2024
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
Alejandra G Serrano, Pedro Rocha, Cibelle Freitas Lima, et al.
Cancer Cell
|
January 22, 2021
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M Gay, C Allison Stewart, Elizabeth M Park, et al.
Nature Medicine
|
June 1, 2026
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
Lauren Averett Byers, Byoung Chul Cho, Alissa J Cooper, et al.
Nature Medicine
|
June 29, 2026
Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
Lauren Averett Byers, Byoung Chul Cho, Alissa J Cooper, et al.
JCO Precision Oncology
|
April 23, 2026
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity
Mitchell Parma, Kaiwen Wang, Ceylan Altintas Taslicay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 24, 2012
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance
Lauren Averett Byers, Lixia Diao, Jing Wang, et al.
Cancer Cell
|
March 7, 2003
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
Andreas Rosenwald, George Wright, Adrian Wiestner, et al.
Page
of 31
Search research articles
Search
Showing results (251-260 of 304) with videos related to
Sort By:
Page
of 31
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 18, 2021
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology
C Allison Stewart, Carl M Gay, Kavya Ramkumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 16, 2024
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities
C Allison Stewart, Lixia Diao, Yuanxin Xi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 3, 2016
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer
Vassiliki Papadimitrakopoulou, J Jack Lee, Ignacio I Wistuba, et al.
NPJ Precision Oncology
|
November 18, 2024
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
Alejandra G Serrano, Pedro Rocha, Cibelle Freitas Lima, et al.
Cancer Cell
|
January 22, 2021
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M Gay, C Allison Stewart, Elizabeth M Park, et al.
Nature Medicine
|
June 1, 2026
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
Lauren Averett Byers, Byoung Chul Cho, Alissa J Cooper, et al.
Nature Medicine
|
June 29, 2026
Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
Lauren Averett Byers, Byoung Chul Cho, Alissa J Cooper, et al.
JCO Precision Oncology
|
April 23, 2026
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity
Mitchell Parma, Kaiwen Wang, Ceylan Altintas Taslicay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 24, 2012
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance
Lauren Averett Byers, Lixia Diao, Jing Wang, et al.
Cancer Cell
|
March 7, 2003
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
Andreas Rosenwald, George Wright, Adrian Wiestner, et al.
Page
of 31